Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.

The conversation discusses taurine supplements for hair growth, highlighting their potential to reduce DHT and improve hair health. A user comments that people often try alternatives to finasteride.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user inquires if RENU Biogen is a DHT inhibitor.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

Finasteride works by reducing DHT, which helps stop hair miniaturization. The user is on finasteride and believes it works due to its effect on growth factors and DHT reduction.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

Stress can increase androgen sensitivity, potentially worsening hair loss. Treatments discussed include Minoxidil, finasteride, and RU58841.

A user with hair loss is considering starting a business selling hair loss treatments, including RU58841, low-dose topical finasteride with optional minoxidil and tretinoin, and topical melatonin. They are also contemplating offering Pyrilutamide and other unique topicals, seeking feedback on interest and suggestions for their potential store.

Topical finasteride can reduce scalp DHT as effectively as oral finasteride with fewer systemic effects, but availability is limited. Some users make their own solutions due to limited access.

The user is experiencing hair shedding while using finasteride and topical minoxidil with tretinoin, keto shampoo, and dermarolling. They hope the shedding indicates future hair regrowth.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

User experienced hair thickening and slight regrowth using RU58841, Fin, DUT, and Minoxidil. They plan to get a hair transplant in Turkey for further improvement.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.

A user with diffuse hair loss after taking accutane, which might have triggered genetic predisposition to AGA; their experience taking finasteride and experiencing side effects of increased oil production, increased sex drive, worsening hair texture; they are considering zinc supplementation with finasteride or other treatments such as alfatradiol or spironolactone.

Scientists discover SCUBE3 molecule for potential baldness cure. Mice used in research for hair growth signaling.

The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.

The conversation discusses the use of 5-alpha-reductase inhibitors like finasteride and dutasteride for hair loss in transgender women, particularly in relation to testosterone suppression. The original poster has been using dutasteride and is considering stopping it due to undetectable testosterone levels.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

Whether topical caffeine can be as effective for hair growth as minoxidil and finasteride, with various replies discussing the efficacy of these treatments and criticism of Dr. Huberman's research methods.

Reducing the dose of RU58841 from 25mg to 7.5mg topically helped minimize heart palpitations. Users discussed the cardiac effects of RU58841 and minoxidil, noting that no treatment is completely free of side effects.

RU58841 is discussed as a hair loss treatment, with users considering lower doses like 2.5% to reduce costs. Some users suggest that if already blocking DHT, lower doses might still be effective unless there's high sensitivity to DHT.

Copper peptides, specifically GHK-Cu, are discussed as a potential addition to hair loss treatments, possibly working synergistically with Minoxidil to convert vellus hair into terminal hair. The effectiveness and credibility of copper peptides are questioned due to the lack of widespread discussion and potential conflict of interest from the product's creator.

Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.

Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.

Minoxidil-dependent hairs fall out if minoxidil is stopped. New treatments like GT20029, FOL055, or TDM105795 might help sustain these hairs.

The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.